HomeInvestors & MediaNews
ABL Bio to Host ADC Symposium
- Global ADC development experts invited as speakers to enhance ADC R&D capabilities March 10, 2025, ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that it will host an ‘Antibody-Drug Conjugate (ADC) Symposium’ for biotech industry officials on March 14th. The symposium is held to enhance ADC development capabilities, which are increasingly gaining attention in the field of oncology drug development and facilitate collaboration among domestic and international ADC experts. Renowned scientists with experience developing ADCs at global pharmaceutical biotech companies will participate as session speakers. The first session, titled ‘The Past, Present, and Future of ADCs,’ will be led by Dr. Mark Sliwkowski, a former scientist at Genentech and member of the Roche Group. Dr. Sliwkowski will share insights into the history of ADCs, the success of HER2-targeted ADC Kadcyla (T-DM1), and lessons learned from past ADC development failures. The second session, titled ‘ADCs for Cancer Treatment,’ will feature Dr. Peter Senter, former scientist of Seagen and Bristol Myers Squibb, who played a key role in the development and approval of ADCs such as Padcev and Tivdak. The third session, "Insights into Clinical ADC Development," will be presented by Dr. Patrick Zweidler-McKay, a former executive at ImmunoGen, the company behind Elahere, a folate receptor alpha (FRα)-targeting ADC. Dr. Zweidler-McKay, now a consultant at his own firm, will discuss ADC clinical development for solid tumors and the therapeutic advantages of ADCs. In the fourth session, Dr. Morris Rosenberg, who previously worked at Immunomedics (developer of the TROP2-targeting ADC Trodelvy) and Seagen, will share strategies for late-stage development of ADC pipelines. The fifth and sixth sessions will cover key considerations in preclinical ADC development and clinical pharmacology of ADCs. Speakers include Dr. Laurie Tatalick, co-founder of ProfoundBio, and Dr. Tae Han, former expert of Seagen. The seventh session will feature Kai Ming-Pu, a consultant from Clearview, a global healthcare consulting firm, who will present emerging trends in ADC development. Last July, ABL Bio announced the full-scale launch of its bispecific ADC development program and secured KRW 140 billion through a third-party allotment capital increase. The company is currently recruiting executives and ADC experts for its U.S. subsidiary, ABL Bio USA, which will spearhead bispecific ADC development. ABL Bio plans to begin IND submissions for its bispecific ADC pipeline starting later this year. Sang Hoon Lee, CEO of ABL Bio said, “As the importance of ADCs in cancer drug development continues to grow, we have invited top international experts to help strengthen the capabilities of our researchers and others in the biotech industry. We’ve prepared this event to be practically helpful for ADC R&D, so we ask for a great deal of interest and participation.”
2025-03-10ablbio
ABL Bio Presents 4-1BB Bispecific Antibody Platform Grabody-T at PEGS Europe
- Grabody-T overcomes liver toxicity of 4-1BB monoclonal antibodies through bispecific structure- Clinical development of 4-1BB bispecific antibodies is progressing well… Company exploring various business opportunities November 8, 2025, ABL Bio (CEO Sang Hoon Lee), ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that it participated in the 16th Annual Protein & Antibody Engineering Summit (PEGS Europe), held in Barcelona, Spain, from November 5th to November 7th. PEGS Europe is the largest European event where industry experts and global pharmaceutical and biotech companies gather to share expertise and the latest insights on protein and antibody engineering. ABL Bio CEO Sang Hoon Lee personally attended the event and delivered an oral presentation in the session titled "Antibody-based Cancer Therapies: Overcome Efficacy and Toxicity Challenges," introducing the company’s 4-1BB-based bispecific antibody platform, Grabody-T. The title of the presentation was: "4-1BB T cell Engaging BsAb (Grabody-T) Activated T Cells only in the Tumor Microenvironment and Demonstrated Superior Efficacy and Safety Profile." 4-1BB is a protein involved in the activation of T cells, a type of immune cell. 4-1BB monoclonal antibodies work by stimulating T cells to attack cancer cells. The first developer of a 4-1BB monoclonal antibody was Bristol Myers Squibb, whose candidate demonstrated strong anticancer efficacy. However, due to severe liver toxicity caused by 4-1BB activation in the liver, clinical development was halted. Grabody-T was developed in a bispecific antibody format to overcome these limitations of 4-1BB monoclonal antibodies. Bispecific antibodies can be designed to target tumor antigens such as Claudin18.2 or HER2, ensuring that T cell activation occurs only within the tumor microenvironment. Clinical-stage bispecific immuno-oncology drug candidates based on Grabody-T include Ragistomig, Givastomig, ABL103, and ABL105. Notably, interim Phase 1 clinical results for Givastomig, presented at the European Society for Medical Oncology (ESMO), showed no serious liver toxicity. Currently, Givastomig is in a Phase 1b clinical trial in the U.S., in combination with chemotherapy and nivolumab. Ragistomig is undergoing a Phase 1 monotherapy trial in the U.S. and Korea. ABL103 is in a domestic Phase 1 monotherapy trial, while ABL105 is in a Phase 1/2 trial led by license partner Yuhan Corporation in Australia and Korea. CEO Sang Hoon Lee stated, “We are pleased to introduce our 4-1BB based bispecific antibody platform to antibody experts around the world. ABL Bio is overcoming the intrinsic liver toxicity challenges of 4-1BB- where even global pharmaceutical companies have failed- by developing it in a bispecific format. Although the Grabody-T-based candidates are still in Phase 1, they are already showing promising clinical data, which has led to clinical collaboration and supply agreements with global pharma. This demonstrates the broader potential value of other 4-1BB bispecific antibodies. We will continue to promote the value of the Grabody-T platform and seek out various business opportunities moving forward.”
2024-11-08ablbio
ABL Bio and I-Mab Presented Encouraging Phase 1 ABL111 Data at ESMO 2024
- Expanded Phase 1 study showed promising single-agent, ABL111 monotherapy activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levels- Confirming 7 partial responses and 14 stable diseases in phase 1 clinical trial for ABL111 monotherapy- A Phase 1b study, evaluating ABL111 in combination with standard-of-care treatment (nivolumab + chemotherapy (FOLFOX)) in front-line gastric cancers, is ongoing ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that its global partner I-Mab presented a poster presentation highlighting encouraging top-line results from the ongoing Phase 1 clinical trial of ABL111 (Givastomig / TJ033721) in patients with advanced solid tumors, especially gastric cancers (including gastroesophageal carcinoma) at the European Society for Medical Oncology 2024 (ESMO 2024) held in Barcelona, Spain from September 13 to 17. ABL111 is a bispecific antibody developed using the Company’s Grabody-T platform. This antibody targets Claudin18.2-positive tumor cells that conditionally activates T cells via 4-1BB in the tumor microenvironment, where Clauin18.2 is expressed. It is being jointly developed by ABL Bio and I-Mab. The interim results of the Phase 1 trial for ABL111were first disclosed at ESMO 2023, and a Phase 1b clinical trial a combining ABL111 plus nivolumab plus chemotherapy (FOLFOX) is currently underway in the U.S. and China. The poster focused on 43 patients enrolled in the dose expansion study (doses ranging from 5 mg/kg to 18 mg/kg) with gastric cancers, including advanced gastroesophageal carcinoma (GEC). Study data indicates that ABL111 has a strong overall safety profile. No dose-limiting toxicity was reported up to 15 mg/kg Q2W and 18 mg/kg Q3W, and a maximum tolerated dose (MTD) was not identified. The most common treatment-related adverse events were nausea (25.6%), anemia (23.3%), and were mainly Grade 1 or Grade 2. In terms of efficacy, among 43 patients with Claudin18.2-positive gastric and esophageal cancer, seven patients reported partial responses (one at 5 mg/kg, one at 8 mg/kg, four at 12 mg/kg, and one at 18 mg/kg), and 14 patients confirmed as stable diseases. Five of the seven patients who had achieved a partial response (71%) had previously received a checkpoint inhibitor. Sang Hoon Lee, CEO of ABL Bio said “We are pleased by the promising monotherapy efficacy results of the Phase 1 clinical trial for ABL111 presented at ESMO 2024. These data build on positive results from last year’s ESMO congress and provide encouraging data, with a strong overall safety profile. Based on the encouraging initial efficacy signals and overall safety profile for ABL 111, we believe ABL111 has the potential to be a front-line treatment option for patients with gastric cancers. We are enthusiastic about the ongoing combination clinical trial of ABL111 plus nivolumab plus chemotherapy and will do our best to accelerate clinical development through close cooperation with I-Mab.” About ABL BioABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. More than 15 clinical projects for over 7 pipelines, including ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. ABL’s lead program, ABL001, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to support the rapid development of this new drug candidate. The program recently completed patient enrollment in a Phase 2/3 clinical trial for biliary tract cancer and the top-line data will be disclosed in 2025. In addition, encouraging Phase 1b data were just presented at ESMO2024 for ABL111, in development with I-Mab for gastric cancers (including gastroesophageal junction, GEJ). Meanwhile, ABL Bio is preparing to initiate clinical trials for ABL104. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs). Note: this is a translated version of the original Korean language document, prepared and provided solely for readers’ convenience. In case of any discrepancy or dispute, the Korean document prevails.
2024-09-20ablbio
ABL Bio’s Global Partner Compass Therapeutics Completes Patient Enrollment for Phase 2/3 C...
- Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel in patients with advanced Biliary Tract Cancer- Approved an Investigator Sponsored Trial of CTX-009 in the first-line setting in patients with Biliary Tract Cancer ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that its global partner, Compass Therapeutics has completed planned enrollment of 150 patients in COMPANION-002, a randomized Phase 2/3 clinical trial of CTX-009 (ABL001) in patients with previously treated, unresectable advanced metastatic or recurrent biliary tract cancers. In addition, along with the completion of enrollment of patients in COMPANION-002, Compass Therapeutics announced the approval of a new Investigator Sponsored Trial (IST) evaluating CTX-009 as a first-line treatment for patients with biliary tract cancer. The clinical trial will be conducted at the MD Anderson Cancer Center at the University of Texas, USA. CTX-009 will be added to gemcitabine, cisplatin, and durvalumab, which is the current standard first-line treatment for biliary tract cancer. CTX-009, initially developed by ABL Bio, is a bispecific antibody targeting VEGF-A (Vascular Endothelial Growth Factor A) and DLL4 (Delta-Like Ligand 4) which induces the death of tumor cells by inhibiting the creation of new blood vessels in cancer. Compass Therapeutics, which holds global rights, is currently conducting a phase 2/3 clinical trial for biliary tract cancer patients in the United States based on the phase 2 clinical trial (HDB001A) conducted in Korea by Handok, which holds Korean rights. CTX-009 received Fast Track Designation from the U.S. Food and Drug Administration (FDA) in April to support the rapid development of new drugs by developers, and an additional phase 2 clinical trial for patients with colorectal cancer is also underway. Sang Hoon Lee, CEO of ABL Bio said “Compass Therapeutics has completed patient enrollment in COMPANION-002. We would like to thank the patients and their families who participated in the clinical trial, and all those involved who helped make it run smoothly. In addition, we are very pleased to announce plans to expand the clinical investigation of CTX-009 to first-line treatment with MD Anderson, one of the most prestigious cancer centers in the United States. We will continue to do our best to quickly share news regarding the progress of CTX-009 clinical development.” About ABL Bio ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. More than 15 clinical projects for over 7 pipelines, including ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. In the case of ABL001, the U.S. Food and Drug Administration (FDA) recently granted Fast Track designation to support the rapid development of this new drug candidate. Meanwhile, ABL Bio is preparing to initiate clinical trials for ABL104. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs). Note: this is a translated version of the original Korean language document, prepared and provided solely for readers’ convenience. In case of any discrepancy or dispute, the Korean document prevails.
2024-08-09ablbio
ABL Bio completes paid-in capital increase allocated to a third party for development of nex...
- The newly issued shares will be protected through the Korea Securities Depository for one year- Investment of paid-in capital increase in development of next-generation ADCs…existing BsAb will be developed based on upcoming milestones and new license-out upfront ABL Bio (CEO Sang Hoon Lee), a company specializing in BsAbs, announced on the 11th that it has completed payment for a paid-in capital increase allocated to a third party worth 140 billion won. Accordingly, ABL Bio will issue 5,778,196 shares of convertible preferred stock (CPS) with no obligation to repay to KDB Bank, Atinum Investment, Intervest, Hana FInancial Group, and Company K Partners. This will be protected by the Korea Securities Depository for one year. Convertible preferred stock will not be listed until the conversion right is exercised after the end of the protection period. On the 2nd, ABL Bio announced a paid-in capital increase through third-party allocation and officially began developing next-generation ADCs (Antibody Drug Conjugates), including bispecific ADCs (BsADCs). BsADCs are a next-generation modality that is expected to show improved safety and superior efficacy compared to the existing monoclonal ADCs by rapidly penetrating two different antigens into the target cancer cells. No drugs in this modality have yet been approved by regulatory agencies, and most candidates are being developed in early clinical stages. On the other hand, the economic value is so great that the Chinese bio company received a upfront of $800 million from global big pharma for a relocation of the global rights of the BsADC going through phase 1 clinical trials in the U.S. ABL Bio plans to proactively invest the funds secured through capital increase in accelerating the development of next-generation ADCs to dominate the global BsADCs market. Meanwhile, the existing 4-1BB-based bispecific immunotherapy drugs and blood brain barrier (BBB) shuttle platform ‘Grabody-B’ will be developed based on upcoming milestone, and upfront for additional license-out. Representative 4-1BB-based bispecific antibodies ABL503 and ABL111 are undergoing phase 1 clinical trials to evaluate the tumor expansion part and triple combination therapy, respectively. As the domestic phase 1 clinical trial of ABL103, another 4-1BB bispecific antibodies, and the Korean and Australian phase 1 clinical trial of ABL105 being developed by Yuhan Corporation, are also progressing smoothly. ABL Bio is confident that this paid-in capital increase will be an important source of momentum towards their maturation into a global bio company. Sang Hoon Lee,the CEO of ABL Bio, said, “the first paid-in capital increase since listing in 2018 has been completed with payment. The remaining task for ABL Bio is to accelerate the development and dominate the BsADC market. Using our BsAb expertise and ADC development experience, we will apply for clinical trials (INDs) for at least three BsADCs by 2025, and focus on developing monoclonal ADCs that use new targets. About ABL Bio ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. More than 15 clinical projects for over 7 pipelines, including ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. In the case of ABL001, the U.S. Food and Drug Administration (FDA) recently granted Fast Track designation to support the rapid development of this new drug candidate. Meanwhile, ABL Bio is preparing to initiate clinical trials for ABL104. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs). Note: this is a translated version of the original Korean language document, prepared and provided solely for readers’ convenience. In case of any discrepancy or dispute, the Korean document prevails.
2024-07-11ablbio
ABL Bio’s Partner, I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Giv...
- I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer- Collaboration builds on promising safety and efficacy data from the givastomig monotherapy study reported at the European Society of Medical Oncology Congress 2023 Seongnam-si, Gyeonggi-do, June 7, 2024 – ABL Bio’s Partner, I-Mab (NASDAQ: IMAB), today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY). The collaboration will evaluate the combination of givastomig (ABL111), an investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by ABL Bio and I-Mab, with Bristol Myers Squibb’s immune checkpoint inhibitor, nivolumab, and chemotherapy (FOLFOX or CAPOX), as a potential first-line treatment for patients with advanced Claudin 18.2-positive gastric and esophageal cancers. Under the terms of the agreement, the study will be a multi-national Phase 1 study conducted by I-Mab. Bristol Myers Squibb will supply nivolumab. Nivolumab is an immune checkpoint inhibitor that is designed to block the PD-L1 protein on cancer cells from binding to PD-1, enhancing T-cell function and resulting in improved anti-tumor responses. “We are pleased to enter into this clinical collaboration agreement with Bristol Myers Squibb as we embark on the next stage of givastomig’s development to explore the significant promise of this bispecific antibody in a triple-therapy regimen,” said Raj Kannan, CEO of I-Mab. “The study builds on the encouraging single-agent activity and safety we have observed with givastomig as presented at ESMO 2023. We remain optimistic that givastomig in combination with nivolumab and chemotherapy will drive potent anti-tumor activity in specific tumors, and we look forward to accelerating progress in the clinic.” ### About ABL BioABL Bio is developing various clinical and non-clinical assets based on the bispecific antibody platform ‘Grabody’. More than 15 clinical projects for more than 7 assets, including ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. In the case of ABL001, the U.S. Food and Drug Administration (FDA) recently granted Fast Track designation to support the rapid development of new drugs. Assets such as ABL104 are also preparing to enter clinical trials. In addition, ABL Bio is continuously researching and developing several other non-clinical drugs, including bispecific ADCs. About GivastomigGivastomig, also known as TJ-CD4B/ABL111 or TJ033721, is a bispecific antibody designed to bind to Claudin 18.2 (CLDN18.2) as a tumor engager and 4-1BB as a conditional T-Cell activator. Givastomig uniquely binds to tumor cells expressing various levels of CLDN18.2, including gastric cancer and pancreatic cancer cells, and conditionally activates intra-tumoral T-cells at the tumor site through 4-1BB. Givastomig appears to effectively maintain a strong tumor binding property and anti-tumor activity attributable to a synergistic effect of both CLDN18.2 antibody and 4-1BB antibody while avoiding or minimizing liver toxicity and systemic immunotoxicity commonly seen with 4-1BB antibodies as a drug class. Developed through a collaboration between I-Mab and ABL Bio, a clinical-stage biotechnology company in South Korea, givastomig is currently being investigated in a Phase 1 clinical study in the U.S. and China. In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for givastomig for the treatment of gastric cancer, including cancer of the gastroesophageal junction.
2024-06-07ablbio
ABL Bio To Present Phase 1 Data for ABL503 at ASCO 2024
- Poster to outline interim Phase 1 results for ABL503 (ragistomig) monotherapy in patients with advanced solid tumors- ABL503 is a bispecific antibody that combines two immune-oncology targets, PD-L1 and 4-1BB, based on ABL Bio’s proprietary Grabody-T platform technology- Data will be presented at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO 2024) in poster session scheduled for June 1, 2024 at 9:00 am CDT ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it will present a poster at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO 2024) regarding the interim results of the phase 1 clinical trial of ABL503 (TJ-L14B, ragistomig), an immunotherapy drug candidate which is being jointly developed with our global partner, I-Mab Biopharma. This is the first disclosure of ABL503 clinical data at a global scientific conference and this data will be presented at ASCO’s Developmental Therapeutics Immunotherapy poster session. ASCO is one of the world's top three cancer societies, and every year, many medical specialists, scientists, multinational pharmaceutical companies, and biotech companies attend and share the latest research results and anticancer drug’s clinical data. It will be held in Chicago from May 31st to June 4th. At this event, ABL Bio will present key data on the Dose Escalation and Dose Expansion portions of the ABL503 study in a poster. The title of the poster is ‘Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors’ and will be released for three hours from 9 a.m. to noon on June 1. ABL503 is a bispecific antibody that simultaneously targets PD-L1 and 4-1BB, which is involved in immune T cell activation. It was developed to overcome the limited response rate and resistance of existing PD-(L)1 treatments, and limit potential 4-1BB off target toxicity. Currently, the phase 1 clinical trial for patients with solid tumors is underway in the United States and Korea. The dose escalation part of the study, which sequentially increases the administered dose, is ongoing in the United States, and the dose expansion part of the study, to assess preliminary antitumor activity of a specific dose for which safety has been confirmed, as well as the tumor expansion part, which is carried out for selected specific cancer types, is ongoing in the United States and Korea. Sang Hoon Lee, CEO of ABL Bio, said, “ABL Bio is excited to share new, promising interim monotherapy results from new data from patients in the Phase 1 program for ragistomig at ASCO 2024, one of the world’s pre-eminent medical meetings. Ragistomig incorporates two powerful targets, PD-L1 and 4-1BB, into our proprietary Grabody-T bispecific antibody technology, ASCO is the second time that data from a product candidate using the 4-1BB bispecific antibody platform, Grabody-T will be presented.” and also stated, “We look forward to sharing the positive results achieved by ABL503 in the phase 1 clinical trial at ASCO.” Meanwhile, ABL Bio is developing various clinical and non-clinical assets based on the bispecific antibody platform ‘Grabody’. More than 15 clinical projects for more than 7 assets, including ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. In the case of ABL001, the U.S. Food and Drug Administration (FDA) recently granted Fast Track designation to support the rapid development of new drugs. Assets such as ABL104 are also preparing to enter clinical trials. In addition, ABL Bio is continuously researching and developing several other non-clinical pipeline drugs, including bispecific ADCs.
2024-05-24ablbio
CStone Announces Presentation of Latest First-in-Human Data for CS5001 (ROR1 ADC) at ASCO 20...
https://www.cstonepharma.com/en/html/news/3693.html https://www.cstonepharma.com/en/html/news/3704.html
2024-05-24ablbio
SITC 2023 successfully ended with ABL Bio and I-Mab introducing ABL503/TJ-L14B and ABL111/TJ...
- ABL503 and ABL111, more powerful anti-cancer effect confirmed when administered in combination- ABL111 will be entered in clinical trial for triple combination therapy as a first-line treatment for gastroesophageal adenocarcinoma ABL Bio (CEO Sanghoon Lee), a company specializing in bispecific antibody, announced that both the Company and its partner I-Mab (NASDAQ: IMAB) have successfully completed its poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) held from November 1 to 5 amid great interest in ABL503 (TJ-L14B) and ABL111 (TJ-CD4B, Givastomig). ABL503 and ABL111 are bispecific antibodies being jointly developed by ABL Bio and Nasdaq-listed company, I-Mab. ABL503 is undergoing phase 1 clinical trials in the United States and Korea, and ABL111 is undergoing phase 1 clinical trials in the United States and China. ABL503 is a bispecific antibody targeting PD-L1 and 4-1BB, and is developed to improve resistance and low response rates, which are considered as limitations of existing PD-(L)1 treatments. According to the ABL503 poster presented by ABL Bio at SITC, the combination therapy of ABL503 and PD-1 treatment appears to have a stronger anticancer effect by enhancing the activation of CD8+ T cells, which are immune cells in the tumor microenvironment. ABL Bio will flesh out its clinical plans for ABL503 combination therapy based on these non-clinical data. ABL111, another bispecific antibody introduced at SITC, simultaneously targets 4-1BB and Claudin18.2 which are overexpressed in gastric cancer, gastroesophageal junction cancer, and esophageal cancer. According to the ABL111 poster presented by I-Mab, T cells activated by ABL111 caused the death of not only Claudin18.2 positive tumor cells but also Claudin18.2 negative tumor cells. In addition, when ABL111 was administrated in combination with chemotherapy and PD-1 treatment, an increase in tumor-infiltrating lymphocytes and enhanced tumor killing effects were confirmed. Based on this, in order to obtain approval for ABL111 as a first-line treatment for gastroesophageal adenocarcinoma, follow-up clinical trials will be conducted on triple combination therapy that simultaneously administers ABL111, chemotherapy, and PD-1 treatment. Sang Hoon Lee, CEO of ABL Bio said “as presented at the SITC, the anticancer effects were found to be stronger when ABL503 administered in combination with immunotherapy, and when ABL111 administered in combination with chemotherapy and immunotherapy. ABL Bio and I-Mab plan to expand clinical trials of ABL503 and ABL111 based on these encouraging results.” And he also said “we will do our best to deliver good news from clinical trials.” Meanwhile, ABL Bio is developing more than 7 pipelines, including ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, and is conducting more than 14 clinical projects with different indications in various countries, including the United States, China, Australia, and Korea. Pipelines such as ABL104 are also preparing to enter clinical trials, and in addition, we are continuing to research and develop several non-clinical pipelines, including ABL102.
2023-11-07ablbio